As insurers limited coverage of behavioral pain therapy, biopharmaceutical producers sensed a chance. Pharmaceutical innovation propagated prolonged-launch formulations, transdermal patches, nasal sprays, and oral dissolving strips. Health care product makers drove a proliferation of novel discomfort-modulating implants. By 2000, Continual discomfo